Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 39

Results For "formulation"

800 News Found

Evonik and BellaSeno advance commercialization of 3D-printed, bioresorbable implants
News | March 09, 2023

Evonik and BellaSeno advance commercialization of 3D-printed, bioresorbable implants

Resomer used in commercial 3D-printed implants for both soft and hard tissue applications


Evonik opens new facility for pharmaceutical lipids in Germany
News | March 09, 2023

Evonik opens new facility for pharmaceutical lipids in Germany

New GMP facility for clinical and small-scale commercial pharmaceutical lipids


Zydus receives final approval from the USFDA for Vigabatrin for Oral Solution
Drug Approval | March 06, 2023

Zydus receives final approval from the USFDA for Vigabatrin for Oral Solution

Vigabatrin for Oral Solution USP, 500 mg had annual sales of US $233.7 mn in US


Zydus receives final approval from the USFDA for Vigabatrin for Oral Solution
Drug Approval | March 04, 2023

Zydus receives final approval from the USFDA for Vigabatrin for Oral Solution

Vigabatrin for Oral Solution USP, 500 mg had annual sales of USD 233.7 mn in the United States


Vaishali Pharma bags Rs 600 crore order for antibiotics pharmaceutical products
News | March 03, 2023

Vaishali Pharma bags Rs 600 crore order for antibiotics pharmaceutical products

This order is subject to initial advance payment as per the agreed terms of the contract and this order will be executed within 6 to 8 months.


Zydus receives final approval from the USFDA for Apixaban Tablets
Drug Approval | March 01, 2023

Zydus receives final approval from the USFDA for Apixaban Tablets

Apixaban Tablets, 2.5 mg and 5 mg had annual sales of USD 18,876 mn in the United States (IQVIA MAT Dec. 2022).


Zydus receives final approval from the USFDA for Hydrochlorothiazide Tablets
Drug Approval | March 01, 2023

Zydus receives final approval from the USFDA for Hydrochlorothiazide Tablets

This combination medicine is used to treat high blood pressure (hypertension).


Briefs: Neuland Laboratories, Cipla and Zydus
Drug Approval | February 20, 2023

Briefs: Neuland Laboratories, Cipla and Zydus

Cipla has received 8 inspectional observations in Form 483